<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704545</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2017-03/JMK-01</org_study_id>
    <nct_id>NCT03704545</nct_id>
  </id_info>
  <brief_title>Clinical Impact of Pharmaceutical Consultations in Patients Treated for Chronic Obstructive Pulmonary Disease at Home</brief_title>
  <acronym>BPCObs</acronym>
  <official_title>Clinical Impact of Pharmaceutical Consultations in Patients Treated for Chronic Obstructive Pulmonary Disease at Home</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The implementation of pharmaceutical consultations in the city or at the hospital could
      modify the occurrence of exacerbations related to chronic obstructive pulmonary disease after
      return of the patient to his home.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of exacerbation events</measure>
    <time_frame>Month 3</time_frame>
    <description>Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of exacerbation events</measure>
    <time_frame>Month 6</time_frame>
    <description>Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of exacerbation events</measure>
    <time_frame>Month 9</time_frame>
    <description>Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of exacerbation events</measure>
    <time_frame>Month 12</time_frame>
    <description>Exacerbation events will be defined as any episode of increased respiratory symptoms, especially dyspnea, cough and sputum production, and increased sputum purulence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the attending physician</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the attending physician</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the attending physician</measure>
    <time_frame>Month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the attending physician</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the pulmonologist</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the pulmonologist</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the pulmonologist</measure>
    <time_frame>Month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the pulmonologist</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the hospital emergency service</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the hospital emergency service</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the hospital emergency service</measure>
    <time_frame>Month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the hospital emergency service</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalisation events</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalisation events</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalisation events</measure>
    <time_frame>Month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalisation events</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Possession Ratio</measure>
    <time_frame>12 months</time_frame>
    <description>unit = percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability score of devices</measure>
    <time_frame>Month 3</time_frame>
    <description>Score between 0 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability score of devices</measure>
    <time_frame>Month 6</time_frame>
    <description>Score between 0 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability score of devices</measure>
    <time_frame>Month 9</time_frame>
    <description>Score between 0 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability score of devices</measure>
    <time_frame>Month 12</time_frame>
    <description>Score between 0 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>Month 1</time_frame>
    <description>The quality of life questionnaire BPCO-VQ11 is composed of 11 items. Each item is scored in a 5 point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>Month 6</time_frame>
    <description>The quality of life questionnaire BPCO-VQ11 is composed of 11 items. Each item is scored in a 5 point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>Month 12</time_frame>
    <description>The quality of life questionnaire BPCO-VQ11 is composed with11 items. Each item is scored in a 5 point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>device usage learning curve</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>satisfaction questionnaire</measure>
    <time_frame>Month 12</time_frame>
    <description>This questionnaire is composed with 4 questions. Each item is scored in a 4 point scale.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group from the hospital</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group from the city</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmaceutical consultation at the hospital</intervention_name>
    <description>During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.</description>
    <arm_group_label>Experimental group from the hospital</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmaceutical consultation at the pharmacy</intervention_name>
    <description>During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.</description>
    <arm_group_label>Experimental group from the city</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow-up pharmaceutical consultation at the pharmacy</intervention_name>
    <description>During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.</description>
    <arm_group_label>Experimental group from the city</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has signed the consent form.

          -  The patient is affiliated to a health insurance programme

          -  The patient is at least 18 years old (≥).

          -  The patient is admitted to complete hospitalization (for patients in the &quot;Hospital and
             Control&quot; groups).

          -  The patient is diagnosed with stage 2 to 4 Chronic Obstructive Pulmonary Disease. The
             diagnosis as well as the stage of the disease are validated by a pulmonologist at the
             facility.

          -  The patient has one or more inhaler devices to treat Chronic Obstructive Pulmonary
             Disease.

          -  The patient returns to his / her home when discharged from hospital (for patients in
             the &quot;Hospital and Control&quot; groups).

          -  The patient is available for a follow-up of 12 months.

        Exclusion Criteria:

          -  The subject participates in another interventional study.

          -  The subject is in an exclusion period determined by a previous study.

          -  The patient is under safeguard of justice.

          -  The subject refuses to sign the consent.

          -  It is not possible to give the patient (or his/her trusted-person) informed
             information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Marie KINOWSKI</last_name>
    <phone>+33(0)4.66.68.31.04</phone>
    <email>jean.marie.kinowski@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nimes University Hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>+33 (0)4.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marie Kinowski, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florent Dubois, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clarisse Roux-Marson, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine LEGUELINEL-BLACHE, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie PLOUVIER, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice RAY, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2018</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

